Neuland Laboratories Limited
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
What Neuland files
- Others73
- Investor Meet46
- Important30
- Updates16
- PPTs8
- Board Meeting8
Neuland Labs' board met, approving Q1 consolidated net profit of ₹147.67 Cr on revenue of ₹641.58 Cr. They've greenlit a ₹40 Cr corporate guarantee for a Gland Pharma sterile API partnership & a ₹39.8 Cr capacity expansion at Unit 1.
Neuland Labs' board approved consolidated FY26 results with Revenue at ₹2023 Cr & PAT at ₹364 Cr. They declared a final dividend of ₹34/share and plan a ₹143.4 Cr capacity expansion at Unit 1. Dr. Mauricio Futran was appointed as a new director.
Neuland Labs' board approved audited FY26 consolidated results: Revenue at ₹2,022.98 Cr, PAT at ₹363.99 Cr. It proposed a ₹34/share final dividend and plans a ₹143.4 Cr capacity expansion at Unit 1 for demand growth. Dr. Mauricio Futran was also appointed to the board.
Neuland Labs' Board approved FY26 consolidated results: Revenue ₹2022.98 Cr, Profit ₹363.99 Cr, EPS ₹283.71. A final dividend of ₹34/share was proposed. Dr. Mauricio Futran appointed as Additional Director. Capacity at Unit 1 will expand by 120.5 KL with ₹143.4 Cr investment. AGM on Aug 4, 2026.
Neuland Labs' Board approved Q3 FY26 consolidated results. Revenue from operations for the quarter stood at ₹439.71 Cr, with a profit of ₹40.57 Cr. For the nine months, revenue was ₹1246.74 Cr and profit was ₹151.33 Cr.